Anti-CD79 antibodies and their uses

AU2026204153A1Pending Publication Date: 2026-08-13NEPENTHE BIOSCI LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-05-28
Publication Date
2026-08-13

Smart Images

  • Figure 00000061_0000
    Figure 00000061_0000
  • Figure 00000062_0000
    Figure 00000062_0000
  • Figure 00000063_0000
    Figure 00000063_0000
Patent Text Reader

Abstract

Abstract The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a 5 therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders. Abstract 20 26 20 41 53 28 M ay 2 02 6 A b s t r a c t 2 0 2 6 2 0 4 1 5 3 2 8 M a y 2 0 2 6 5
Need to check novelty before this filing date? Find Prior Art